Bifalgorithm post · ASCO 2026: Studies Aim to Expand Treatment Options for Lung Cancer · TRITON: Tremelimumab Plus Durvalumab and Chemotherapy

Safety Outlook

Safety Outlook (ASCO 2026: Studies Aim to Expand Treatment Options for Lung Cancer · TRITON: Tremelimumab Plus Durvalumab and Chemotherapy) — "The incidence of…

Ideas in this flowchart

Safety findings and remaining uncertainty in the treatment arms
Adverse-event incidence was similar between the treatment arms
Discontinuation rates were low
Treatment-related adverse events caused 3 discontinuations: 1 in D+T+CT and 2 in P+CT
One patient death occurred in the P+CT group
No new safety signals were observed
Larger numbers and longer follow-up may clarify whether CTLA-4-containing regimens improve outcomes in molecularly defined subgroups
There is an unmet need for treating tumors with STK11 and KEAP1 mutations that may confer resistance to immunotherapy

Bifalgorithm

Feed/

Safety Outlook

No cover

Channel

ASCO 2026: Studies Aim to Expand Treatment Options for Lung Cancer

1 page

USR292600b83e2a

Ebook2w

"The incidence of adverse events was similar between the treatment arms, with low rates of discontinuation and no new safety signals, he said. The incidence of adverse events was similar between the 2 study arms, with TRAEs leading to 3 treatment discontinuations (1 in the D+T+CT group and 2 in the P+CT group) and 1 patient death (in the P+CT group). “With larger numbers and longer follow-up, we may have a clearer sense of whether CTLA-4-containing regimens can meaningfully improve outcomes for these molecularly defined subgroups,” Dr Schoenfeld said. “There’s certainly an unmet need for treating tumors harboring mutations like STK11 and KEAP1 that appear to confer some degree of resistance to immunotherapy,” agreed Dr Neal."

Flowchart preview

👍

0 comments0 shares